Journal
MOLECULAR CELL
Volume 78, Issue 5, Pages 824-+Publisher
CELL PRESS
DOI: 10.1016/j.molcel.2020.03.030
Keywords
-
Categories
Funding
- Stanford University
- Stanford ChEM-H
- University of California, Berkeley
- Howard Hughes Medical Institute
- National Institutes of Health [R01 CA200423, R21 DK112733]
- Defense Threat Reduction Agency [GRANT11631647]
- Francis Crick Institute from Cancer Research UK [FC001749]
- UK Medical Research Council [FC001749]
- Wellcome Trust [FC001749]
- U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-AC02-76SF00515]
- DOE Office of Biological and Environmental Research
- National Institutes of Health, National Institute of General Medical Sciences [P41GM103393]
- ALS-ENABLE program - National Institutes of Health, National Institute of General Medical Sciences [DE-AC0205CH11231, P30 GM124169-01]
- Feodor Lynen Fellowship by the Alexander von Humboldt Foundation
- Banting Postdoctoral Fellowship from the Canadian Institutes of Health Research
- National Institute of General Medical Sciences F32 Postdoctoral Fellowship [F32-GM126663-01]
- NWO Rubicon Postdoctoral Fellowship
- Stanford ChEM-H undergraduate scholarship
- National Institutes of Health Postdoctoral Fellowship [5F32CA224985]
- National Science Foundation Graduate Research Fellowship
- Stanford ChEM-H Chemistry/Biology Interface Predoctoral Training Program
- Stanford Graduate Fellowship
Ask authors/readers for more resources
Studying posttranslationalmodifications classically relies on experimental strategies that oversimplify the complex biosyntheticmachineries of living cells. Protein glycosylation contributes to essential biological processes, but correlating glycan structure, underlying protein, and disease-relevant biosynthetic regulation is currently elusive. Here, we engineer living cells to tag glycans with editable chemical functionalities while providing information on biosynthesis, physiological context, and glycan fine structure. We introduce a non-natural substrate biosynthetic pathway anduse engineered glycosyltransferases to incorporate chemically tagged sugars into the cell surface glycome of the living cell. We apply the strategy to a particularly redundant yet disease-relevant human glycosyltransferase family, the polypeptideN-acetylgalactosaminyl transferases. This approach bestows a gain-of-chemical-functionalitymodification on cells, where the products of individual glycosyltransferases can be selectively characterizedormanipulated to understandglycan contributiontomajorphysiological processes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available